← Back to Search

Janus Kinase (JAK) Inhibitor

Baricitinib for Atopic Dermatitis

Phase 2
Waitlist Available
Research Sponsored by Eli Lilly and Company
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up week (wk) 0: predose, 15-30 minutes (min) postdose; wk 4: 1.5 - 4 hour (hr) postdose; wk 8: 4 - 8 hr postdose; wk 12: predose; wk 16: 30 - 90 min postdose.
Awards & highlights
Approved for 10 Other Conditions
All Individual Drugs Already Approved

Summary

The purpose of this study is to evaluate the safety and effectiveness of Baricitinib in eczema.

Eligible Conditions
  • Atopic Dermatitis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week (wk) 0: predose, 15-30 minutes (min) postdose; wk 4: 1.5 - 4 hour (hr) postdose; wk 8: 4 - 8 hr postdose; wk 12: predose; wk 16: 30 - 90 min postdose.
This trial's timeline: 3 weeks for screening, Varies for treatment, and week (wk) 0: predose, 15-30 minutes (min) postdose; wk 4: 1.5 - 4 hour (hr) postdose; wk 8: 4 - 8 hr postdose; wk 12: predose; wk 16: 30 - 90 min postdose. for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Percentage of Participants With a 50% or Greater Reduction in the Eczema Area and Severity Index (EASI 50)
Secondary study objectives
Change From Baseline in the Dermatologic Life Quality Index (DLQI) at Week 16
Change From Baseline in the EASI at Week 16
Change From Baseline in the Investigator's Global Assessment (IGA) at Week 16
+4 more

Awards & Highlights

Approved for 10 Other Conditions
This treatment demonstrated efficacy for 10 other conditions.
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: BaricitinibExperimental Treatment2 Interventions
Administered once daily in multiple oral dose cohorts for 16 weeks (Triamcinolone 0.1% topical also permitted)
Group II: PlaceboPlacebo Group2 Interventions
Administered orally once daily, for 16 weeks (Triamcinolone 0.1% topical also permitted)
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Triamcinolone
FDA approved
Baricitinib
FDA approved

Find a Location

Who is running the clinical trial?

Eli Lilly and CompanyLead Sponsor
2,677 Previous Clinical Trials
3,465,507 Total Patients Enrolled
Study DirectorEli Lilly and Company
1,388 Previous Clinical Trials
428,000 Total Patients Enrolled
~13 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top